Tuesday, August 4, 2026

Samsung Brings AI Classrooms to Bett 2026: What 35,000 Educators Saw in London

Samsung Electronics showcased AI-powered products at Bett 2026, emphasizing personalized learning and innovative educational technology solutions.

Team USA Wins “Tariff Derby,” Stuns Canada for Olympic Gold

The U.S. men's ice hockey team wins Olympic gold by defeating Canada 2-1 in overtime, ending a 46-year drought.

South Korea–Japan Defense Reset: Yokosuka Talks Bring Back Joint Sea Rescue Drills After a 9-Year Pause

South Korea and Japan's defense ministers agree to enhance U.S. deterrence and resume joint exercises amid rising regional threats.

Tag: GC Cell

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Artiva to Advance NK Cell Therapy Into Phase 3 for Rheumatoid Arthritis After Positive Mid-Stage Data

GC Cell's Artiva Biotherapeutics advances NK cell therapy AlloNK to Phase 3 trials for rheumatoid arthritis after promising Phase 2 results.

GC Cell Secures Japanese Certification for the Manufacture of Specific Cell Processing Products

GC Cell receives final certification from Japan for cell processing products, validating its manufacturing and quality systems for regenerative medicine.

GC Cell Showcases Cold Chain Innovations the Spring Symposium of the Korean Society of Laboratory Medicine

GC Cell, GC Green Cross, and GC Genome showcased innovations in diagnostics at the 2023 Spring Symposium, enhancing precision medicine.

GC Cell’s CAR-NK: Revolutionizing Solid Tumor Treatment with New Patent

GC Cell has patented an immunotherapy targeting solid tumors using its CAR-NK platform, aiming for safer, cost-effective treatments.

GCCell Secures Groundbreaking Patent for Next-Gen Cell Therapy: What It Means for the Future of Immunotherapy

GC Cell has completed the registration of core technology patents for next-gen cell and gene therapies in South Korea and Japan.

GCC2005: The Breakthrough CAR-NK Therapy for T-Cell Lymphoma Unveiled at TCLF 2026

GC Cell presents promising CD5-targeting CAR-NK therapy GCC2005 for T-cell lymphoma, showing significant efficacy and safety at TCLF.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.